The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Subscribe To Our Newsletter & Stay Updated
